Head to Head Survey: Sharps Technology (NASDAQ:STSS) & Delcath Systems (NASDAQ:DCTH)

Sharps Technology (NASDAQ:STSS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Sharps Technology and Delcath Systems’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.84 million	N/A	N/A
Delcath Systems	$2.07 million	57.78	-$47.68 million	($2.97)	-1.64

Sharps Technology has higher earnings, but lower revenue than Delcath Systems.

Profitability

This table compares Sharps Technology and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-103.10%	-76.46%
Delcath Systems	-2,308.86%	-563.60%	-111.13%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sharps Technology and Delcath Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	0	0	1	0	3.00
Delcath Systems	0	0	4	0	3.00

Delcath Systems has a consensus target price of $18.50, indicating a potential upside of 279.88%. Given Delcath Systems’ higher possible upside, analysts clearly believe Delcath Systems is more favorable than Sharps Technology.

Insider & Institutional Ownership

17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 14.1% of Sharps Technology shares are held by insiders. Comparatively, 21.1% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Sharps Technology has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.